Quest for the right Drug
טופמקס 25 TOPAMAX 25 (TOPIRAMATE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
טבליות מצופות פילם : FILM COATED TABLETS
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects The safety of topiramate was evaluated from a clinical trial database consisting of 4,111 patients (3,182 on topiramate and 929 on placebo) who participated in 20 double-blind trials and 2,847 patients who participated in 34 open-label trials, respectively, for topiramate as adjunctive treatment of primary generalised tonic-clonic seizures, partial onset seizures, seizures associated with Lennox-Gastaut syndrome, monotherapy for newly or recently diagnosed epilepsy or migraine prophylaxis. The majority of adverse reactions were mild to moderate in severity. Adverse reactions identified in clinical trials, and during post-marketing experience (as indicated by “*”) are listed by their incidence in clinical trials in Table 1. Assigned frequencies are as follows: Very common ≥1/10 Common ≥1/100 to <1/10 Uncommon ≥1/1,000 to <1/100 Rare ≥1/10,000 to <1/1,000 Not known cannot be estimated from the available data The most common adverse reactions (those with an incidence of >5% and greater than that observed in placebo in at least 1 indication in double-blind controlled studies with topiramate) include: anorexia, decreased appetite, bradyphrenia, depression, expressive language disorder, insomnia, coordination abnormal, disturbance in attention, dizziness, dysarthria, dysgeusia, hypoaesthesia, lethargy, memory impairment, nystagmus, paraesthesia, somnolence, tremor, diplopia, vision blurred, diarrhoea, nausea, fatigue, irritability, and weight decreased. Table 1: Topiramate Adverse Reactions System Organ Very common Common Uncommon Rare Not known Class Infections and nasopharyngitis* infestations Blood and anaemia leucopenia, neutropenia* lymphatic system thrombocytopenia disorders lymphadenopathy, eosinophilia Immune system hypersensitivity allergic disorders oedema* Metabolism and anorexia, decreased metabolic acidosis, acidosis nutrition disorders appetite hypokalaemia, hyperchloraemic, increased appetite, hyperammonaemia*, polydipsia hyperammonaemic encephalopathy* Topamax_spc_Sep2024_ref_EU SmPC Sep2024 Psychiatric depression bradyphrenia, suicidal ideation, mania, panic disorders insomnia, suicide attempt, disorder, feeling of expressive hallucination, despair*, hypomania language disorder, psychotic disorder, anxiety, hallucination confusional state, auditory, disorientation, hallucination aggression, mood visual, apathy, lack altered, agitation, of spontaneous mood swings, speech, sleep depressed mood, disorder, affect anger, abnormal lability, libido behaviour decreased, restlessness, crying, dysphemia, euphoric mood, paranoia, perseveration, panic attack, tearfulness, reading disorder, initial insomnia, flat affect, thinking abnormal, loss of libido, listless, middle insomnia, distractibility, early morning awakening, panic reaction, elevated mood Topamax_spc_Sep2024_ref_EU SmPC Sep2024 Nervous system paraesthesia, disturbance in depressed level of apraxia, circadian disorders somnolence, attention, memory consciousness, rhythm sleep dizziness impairment, grand mal disorder, amnesia, cognitive convulsion, visual hyperaesthesia, disorder, mental field defect, hyposmia, anosmia, impairment, complex partial essential tremor, psychomotor skills seizures, speech akinesia, impaired, disorder, unresponsive to convulsion, psychomotor stimuli coordination hyperactivity, abnormal, tremor, syncope, sensory lethargy, disturbance, hypoaesthesia, drooling, nystagmus, hypersomnia, dysgeusia, balance aphasia, repetitive disorder, speech, dysarthria, hypokinesia, intention tremor, dyskinesia, sedation dizziness postural, poor quality sleep, burning sensation, sensory loss, parosmia, cerebellar syndrome, dysaesthesia, hypogeusia, stupor, clumsiness, aura, ageusia, dysgraphia, dysphasia, neuropathy peripheral, presyncope, dystonia, formication Eye disorders vision blurred, visual acuity blindness unilateral, angle closure diplopia, visual reduced, scotoma, blindness transient, glaucoma*, disturbance myopia*, abnormal glaucoma, maculopathy*, sensation in eye*, accommodation eye movement dry eye, disorder, altered disorder*, photophobia, visual depth conjunctival blepharospasm, perception, oedema*, lacrimation scintillating uveitis increased, scotoma, eyelid photopsia, oedema*, night mydriasis, blindness, presbyopia amblyopia Ear and labyrinth vertigo, tinnitus, deafness, deafness disorders ear pain unilateral, deafness neurosensory, ear discomfort, hearing impaired Cardiac disorders bradycardia, sinus bradycardia, palpitations Vascular disorders hypotension, Raynaud's orthostatic phenomenon hypotension, flushing, hot flush Topamax_spc_Sep2024_ref_EU SmPC Sep2024 Respiratory, dyspnoea, dyspnoea thoracic and epistaxis, nasal exertional, mediastinal congestion, paranasal sinus disorders rhinorrhoea, hypersecretion, cough* dysphonia Gastrointestinal nausea, diarrhoea vomiting, pancreatitis, disorders constipation, flatulence, abdominal pain gastrooesophageal upper, dyspepsia, reflux disease, abdominal pain, abdominal pain dry mouth, stomach lower, discomfort, hypoaesthesia oral, paraesthesia oral, gingival bleeding, gastritis, abdominal abdominal discomfort distension, epigastric discomfort, abdominal tenderness, salivary hypersecretion, oral pain, breath odour, glossodynia Hepatobiliary hepatitis, hepatic disorders failure Skin and alopecia, rash, anhidrosis, Stevens-Johnson toxic epidermal subcutaneous tissue pruritus hypoaesthesia syndrome* erythema necrolysis* disorders facial, urticaria, multiforme*, skin erythema, pruritus odour abnormal, generalised, rash periorbital oedema*, macular, skin urticaria localised discolouration, dermatitis allergic, swelling face Musculoskeletal arthralgia, muscle joint swelling*, limb discomfort* and connective spasms, myalgia, musculoskeletal tissue disorders muscle twitching, stiffness, flank muscular pain, muscle weakness, fatigue musculoskeletal chest pain Renal and urinary nephrolithiasis, calculus urinary, calculus ureteric, disorders pollakiuria, urinary renal tubular dysuria, incontinence, acidosis* nephrocalcinosis* haematuria, incontinence, micturition urgency, renal colic, renal pain Reproductive erectile system and breast dysfunction, sexual disorders dysfunction General disorders fatigue pyrexia, asthenia, hyperthermia, face oedema and administration irritability, gait thirst, influenza site conditions disturbance, feeling like illness*, abnormal, malaise sluggishness, peripheral coldness, feeling drunk, feeling jittery Topamax_spc_Sep2024_ref_EU SmPC Sep2024 Investigations weight decreased weight increased* crystal urine blood bicarbonate present, tandem decreased gait test abnormal, white blood cell count decreased, Increase in liver enzymes Social learning disability circumstances * identified as an adverse reaction from postmarketing spontaneous reports. Its frequency was calculated based on the incidence in clinical trials, or was calculated if the event did not occur in clinical trials. Congenital malformations and foetal growth restrictions (see section 4.4 and section 4.6). Paediatric population Adverse reactions reported more frequently (≥2-fold) in children than in adults in double-blind controlled studies include: • Decreased appetite • Increased appetite • Hyperchloraemic acidosis • Hypokalaemia • Abnormal behaviour • Aggression • Apathy • Initial insomnia • Suicidal ideation • Disturbance in attention • Lethargy • Circadian rhythm sleep disorder • Poor quality sleep • Lacrimation increased • Sinus bradycardia • Feeling abnormal • Gait disturbance. Adverse reactions that were reported in children but not in adults in double-blind controlled studies include: • Eosinophilia • Psychomotor hyperactivity • Vertigo • Vomiting • Hyperthermia • Pyrexia • Learning disability. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form http://sideeffects.health.gov.il
פרטי מסגרת הכללה בסל
א. התרופה תינתן לטיפול באפילפסיה. ב. מתן התרופה ייעשה לפי מרשם של רופא מומחה בנוירולוגיה
מסגרת הכללה בסל
התוויות הכלולות במסגרת הסל
התוויה | תאריך הכללה | תחום קליני | Class Effect | מצב מחלה |
---|---|---|---|---|
א. התרופה תינתן לטיפול באפילפסיה. ב. מתן התרופה ייעשה לפי מרשם של רופא מומחה בנוירולוגיה | 01/03/2021 | נוירולוגיה | אפילפסיה | |
א. לחולי אפילפסיה שאינם מאוזנים על ידי טיפול בשתי תרופות אנטי אפילפטיות מהדור הישן (כמו Valproic acid, Carbamazepine, Phenytoin, Primidone ב. התרופה תינתן על פי מרשם של רופא מומחה בנוירולוגיה | 09/03/1999 | נוירולוגיה | אפילפסיה |
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
09/03/1999
הגבלות
תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת
מידע נוסף